Table 1

Demographic and clinical characteristics of the Regione Emilia-Romagna population, overall and by risk category

 Total population*Very high risk†High risk†
3 726 380114 255134 610
NumberPer centNumberPer centNumberPer cent
Gender
 Male1 788 04848.054 35747.661 80345.9
 Female1 938 33252.059 89852.472 80754.1
Age groups
 18–24258 3386.9760.11050.1
 25–34499 78613.43020.33910.3
 35–44732 62619.711371.011980.9
 45–54676 04718.126122.324851.8
 55–64550 68914.853914.752873.9
 65–74482 34612.913 15411.514 47110.8
 75–84364 3699.833 43029.344 85733.3
 85+162 1794.458 15350.965 81648.9
Number of chronic conditions
 0–12 775 88874.581767.224 61818.3
 2 or more950 49225.5106 07992.8109 99281.7
 5 or more99 3372.745 44539.820 57615.3
Selected conditions/body systems
 Cancer99 3282.723 87220.914 30510.6
 Cardiovascular967 79626.096 15784.2103 74977.1
 Male genitourinary‡130 6097.314 61626.916 77627.1
 Ear, nose, throat53640.12400.22420.2
 Endocrine429 52811.540 65335.637 47127.8
 Eye114 1173.19,5588.413 47810.0
 Gastrointestinal580 94615.674 71865.466 30549.3
 Gynaecological§21 8061.13330.64050.6
 Haematological45 0221.215 35313.465914.9
 Hepatobiliary24 7850.76,4775.733062.5
 Immunological32810.14640.42730.2
 Infectious disease47230.122071.97270.5
 Musculoskeletal419 18411.243 43638.041 00030.5
 Neurological173 7514.734 49430.224 83818.5
 Psychological291 3087.843 38738.033 71525.0
 Respiratory176 8304.739 08234.221 76316.2
 Skin28 3390.87,6456.73,0082.2
 Urogenital37 7281.016 50114.45,7404.3
Polypharmacy¶609 27816.492 15380.792 15668.5
Any potentially inappropriate medications (age 65 years or older)**257 03325.551 05548.749 00339.2
  • *Adults (age 18 or older) and alive at 31 December 2011.

  • †‘Very high risk’ was defined as patients with a predicted risk of hospitalisation or death in the following year of ≥25% while ‘high risk’ was defined as patients with a predicted risk of hospitalisation of 15–24%.

  • ‡Men only.

  • §Women only.

  • ¶Polypharmacy is defined as the simultaneous use of five or more active ingredients for at least 15 consecutive days.

  • **The list of potentially inappropriate medications can be found in ref. 11.